These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 12126722)

  • 41. Drug resistance genotypes predict response to amprenavir-containing regimens in highly drug-experienced HIV-1-infected patients.
    Sabin CA; Wilkins E; Murphy M; Fisher M; de Ruiter A; Easterbrook PJ; Leen C; Vlahakis E; Cane PA; Li X; Pillay D;
    Antivir Ther; 2003 Aug; 8(4):301-8. PubMed ID: 14518699
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of phenotypic and genotypic resistance to antiretroviral therapy in the UNAIDS HIV Drug Access Initiative--Uganda.
    Weidle PJ; Downing R; Sozi C; Mwebaze R; Rukundo G; Malamba S; Respess R; Hertogs K; Larder B; Ochola D; Mermin J; Samb B; Lackritz E
    AIDS; 2003 Jul; 17 Suppl 3():S39-48. PubMed ID: 14565608
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).
    Pellegrin I; Wittkop L; Joubert LM; Neau D; Bollens D; Bonarek M; Girard PM; Fleury H; Winters B; Saux MC; Pellegrin JL; Thiébaut R; Breilh D;
    Antivir Ther; 2008; 13(2):271-9. PubMed ID: 18505178
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.
    Salomon H; Wainberg MA; Brenner B; Quan Y; Rouleau D; Coté P; LeBlanc R; Lefebvre E; Spira B; Tsoukas C; Sekaly RP; Conway B; Mayers D; Routy JP
    AIDS; 2000 Jan; 14(2):F17-23. PubMed ID: 10708278
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antiretroviral resistance mutations in human immunodeficiency virus type 1 infected patients enrolled in genotype testing at the Central Public Health Laboratory, São Paulo, Brazil: preliminary results.
    Rodrigues R; Vazquez CM; Colares JK; Custodio RM; Bonásser Filho F; Souza Ldo R; Gianna MC; Marques CC; Brígido LF
    Mem Inst Oswaldo Cruz; 2005 Feb; 100(1):97-102. PubMed ID: 15867972
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Utility of repeat genotypic resistance testing and clinical response in patients with three class resistance and virologic treatment failure.
    Badri SM; Adeyemi OM; Max BE; Hota BN; Barker DE
    AIDS Patient Care STDS; 2007 Aug; 21(8):544-50. PubMed ID: 17711379
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.
    Dudley DM; Bailey AL; Mehta SH; Hughes AL; Kirk GD; Westergaard RP; O'Connor DH
    Retrovirology; 2014 Dec; 11():122. PubMed ID: 25533166
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV-1 Protease, Reverse Transcriptase, and Integrase Variation.
    Rhee SY; Sankaran K; Varghese V; Winters MA; Hurt CB; Eron JJ; Parkin N; Holmes SP; Holodniy M; Shafer RW
    J Virol; 2016 Jul; 90(13):6058-6070. PubMed ID: 27099321
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.
    Recsky MA; Brumme ZL; Chan KJ; Wynhoven B; Yip B; Dong WW; Heath KV; Montaner JS; Levy AR; Hogg RS; Harrigan PR
    J Infect Dis; 2004 Jul; 190(2):285-92. PubMed ID: 15216463
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution.
    Kantor R; Katzenstein D
    AIDS Rev; 2003; 5(1):25-35. PubMed ID: 12875105
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.
    Hogg RS; Bangsberg DR; Lima VD; Alexander C; Bonner S; Yip B; Wood E; Dong WW; Montaner JS; Harrigan PR
    PLoS Med; 2006 Sep; 3(9):e356. PubMed ID: 16984218
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Update of the drug resistance mutations in HIV-1: 2004.
    Johnson VA; Brun-Vézinet F; Clotet B; Conway B; D'Aquila RT; Demeter LM; Kuritzkes DR; Pillay D; Schapiro JM; Telenti A; Richman DD
    Top HIV Med; 2004; 12(4):119-24. PubMed ID: 15516709
    [No Abstract]   [Full Text] [Related]  

  • 54. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.
    de Baar MP; Janssens W; de Ronde A; Fransen K; Colebunders R; Kestens L; van der Groen G; Goudsmit J
    AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1385-94. PubMed ID: 11018858
    [TBL] [Abstract][Full Text] [Related]  

  • 55. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
    Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
    J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.
    Middleton T; Smith D; Larder B; Law M; Birch C
    HIV Clin Trials; 2001; 2(6):445-52. PubMed ID: 11742431
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study.
    Lorenzi P; Opravil M; Hirschel B; Chave JP; Furrer HJ; Sax H; Perneger TV; Perrin L; Kaiser L; Yerly S
    AIDS; 1999 Feb; 13(2):F17-21. PubMed ID: 10202819
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study.
    Duwe S; Brunn M; Altmann D; Hamouda O; Schmidt B; Walter H; Pauli G; Kücherer C
    J Acquir Immune Defic Syndr; 2001 Mar; 26(3):266-73. PubMed ID: 11242200
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Redistribution of human immunodeficiency virus type 1 variants resistant to protease inhibitors after a protease inhibitor-sparing regimen.
    Gianotti N; Seminari E; Lazzarin A; Boeri E; Clementi M; Danise A; Salpietro S; Fusetti G; Castagna A
    AIDS Res Hum Retroviruses; 2005 Jun; 21(6):545-54. PubMed ID: 15989459
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HIV genotype mutations evoked by nelfinavir-based regimens: frequency, background, and consequences on subsequent treatment options.
    Manfredi R; Calza L
    J Acquir Immune Defic Syndr; 2002 Jun; 30(2):258-60. PubMed ID: 12045690
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.